Below are our currently enrolling studies for patients with rheumatoid arthritis.
/assets/docs/421576.png)
Sponsor: Crescendo Bioscience
Protocol Number: 133-CL-01
In this 12-month multi-center prospective, site-randomized, two-arm trial, approximately 318 biologic-naïve subjects with RA who are candidates for treatment intensification due to inadequate response to MTX monotherapy will be enrolled at up to 60 study sites.
Detailed Information: Here
To learn more or see if you qualify: Click Here
/assets/docs/421578.png)
Sponsor: Eli Lilly
Protocol Number: 14V-MC-JAJD
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Detailed Information: Here
To learn more or see if you qualify: Click Here
Sponsor: XBiotech, Inc.
/assets/docs/421580.png)
Protocol Number: Natrunix 2021-PT055- with MTX
Phase II, Double-Blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination with MTX (+Folate) for the Treatment of Rheumatoid Arthritis
Detailed Information: Here
To learn more or see if you qualify: Click Here